Federal regulators may allow compounding pharmacies to produce popular peptides lacking FDA approval. Doctors cite insufficient data, while proponents argue access ensures safety. An FDA panel will decide on seven peptides, balancing risks against unproven benefits.
FDA panel to decide fate of popular peptide therapies
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →